Testing FB102 for non-segmental vitiligo
Treatments studied
Part of Skin clinical trials.
This study tests a new medicine called FB102 for people with non-segmental vitiligo. It aims to see if the drug is safe and helps restore skin color.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old.
- You have non-segmental vitiligo (patches on both sides of your body).
- If you take other medicines for any reason (not for vitiligo), you must be on a stable dose for at least 7 days before starting the trial.
- You do not have another skin condition (like psoriasis or eczema) that could interfere with the study.
- Your vitiligo patches on your face should not have more than about one-third of the hair turned white.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new medicine called LY4005130 for non-segmental vitiligo, a skin condition where patches lose pigment (color). The trial aims to see if this drug can help restore skin color and stop the spread of white patches.
This trial tests a new medicine called TEV-53408 to see if it can help with vitiligo, a condition that causes white patches on the skin. It may help by restoring skin color, and the study will check how safe and effective it is.
This Phase 2 trial tests whether a new drug called D-2570 can help restore skin color in people with non-segmental vitiligo (when white patches appear randomly across the body). The study will track how well the drug works and check if it's safe to use.
This trial tests an ointment called MH004 to see if it helps repigment white patches in people with non-segmental vitiligo (the most common type). It focuses on patches on the face and body.
This trial tests a new treatment for non-segmental vitiligo that uses a special liquid made from stem cells, applied through tiny needle pricks or small injections, alongside standard light therapy. It may help restore pigment to white patches with fewer side effects than traditional treatments.
This trial tests a new medicine called GR2301, given as an injection, combined with light therapy, to see if it can help people with vitiligo. It aims to improve skin color in affected areas, especially on the face.
Hear when a new Vitiligo trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.